Thus, we performed IHC staining and scoring for activin, TGF-β, and CD4 on 1055 stage II/III CRC patient samples from the QUASAR II cohort to correlate changes in survival to pan-tumoral expression of these markers. This evidence concerns the gene TGFB1 and colorectal carcinoma.